Mirae Asset Global Investments Co. Ltd. purchased a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 32,989 shares of the medical equipment provider's stock, valued at approximately $750,000. Mirae Asset Global Investments Co. Ltd. owned 0.08% of BioLife Solutions at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of BLFS. Allspring Global Investments Holdings LLC bought a new stake in shares of BioLife Solutions during the fourth quarter worth $76,000. Truist Financial Corp bought a new stake in shares of BioLife Solutions during the first quarter worth $208,000. Handelsbanken Fonder AB bought a new stake in shares of BioLife Solutions during the fourth quarter worth $257,000. Sentinel Pension Advisors Inc. grew its holdings in shares of BioLife Solutions by 9.0% during the first quarter. Sentinel Pension Advisors Inc. now owns 12,092 shares of the medical equipment provider's stock worth $275,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Stansberry Asset Management LLC bought a new stake in shares of BioLife Solutions during the fourth quarter worth $276,000. 83.48% of the stock is currently owned by institutional investors.
Get BioLife Solutions alerts:BioLife Solutions Trading Down 5.0 %
NASDAQ BLFS opened at $23.09 on Monday. The firm has a market cap of $983.75 million, a P/E ratio of -10.26 and a beta of 1.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.55 and a quick ratio of 2.54. The stock's 50-day moving average is $18.76 and its 200-day moving average is $18.33. BioLife Solutions, Inc. has a one year low of $10.40 and a one year high of $60.67.
Analyst Upgrades and Downgrades
BLFS has been the topic of several recent research reports. Cowen decreased their price target on BioLife Solutions to $29.00 in a report on Monday, August 15th. Cowen decreased their price target on BioLife Solutions from $50.00 to $32.00 in a report on Tuesday, May 10th. Maxim Group decreased their price target on BioLife Solutions from $60.00 to $30.00 in a report on Thursday, May 12th. Finally, B. Riley decreased their price target on BioLife Solutions from $48.00 to $34.00 in a report on Tuesday, May 17th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $38.00.Insider Transactions at BioLife Solutions
In other news, CRO Marcus Schulz sold 4,600 shares of the firm's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now owns 36,218 shares of the company's stock, valued at $725,446.54. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CRO Marcus Schulz sold 4,600 shares of the stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $20.03, for a total transaction of $92,138.00. Following the completion of the transaction, the executive now directly owns 36,218 shares in the company, valued at $725,446.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Greef Roderick De sold 9,158 shares of the stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total value of $144,604.82. Following the transaction, the chief operating officer now owns 124,458 shares of the company's stock, valued at $1,965,191.82. The disclosure for this sale can be found here. Insiders have sold a total of 18,401 shares of company stock valued at $313,764 over the last 90 days. 3.30% of the stock is owned by company insiders.
BioLife Solutions Company Profile
(Get Rating)
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Articles
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- Why Trading Volume is Unusually High on These 3 Stocks
- Can NetApp Resume Its Rally After Strong Earnings Guidance?
- Three Reasons Why Medtronic Stock can be a Recession Winner
- Rivian Rising to the Challenge
- 3 Deflation Enablers Stocks that Can Thrive in a Recession
Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating).
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.